Check out the latest research updates from the wider community from this month. While we didn’t fund these projects, we’re encouraged to see a continued focus on understanding scleroderma.
Inhaled therapy for Raynaud’s attacks put on FDA fast track
An inhaled form of treprostinil, already approved for pulmonary arterial hypertension, is being tested in a new Phase 2a clinical trial in about 75 adults with systemic sclerosis (SSc) to treat Raynaud’s phenomenon, after receiving FDA fast track designation.
ILC2 and G-MDSC Interactions May Drive Fibrosis in Systemic Sclerosis
Two types of immune cells may work together to drive scarring in systemic sclerosis (SSc), according to a new preprint study in Arthritis & Rheumatology, suggesting a possible new target for treating fibrosis.
Experimental Study Points to Systemic Sclerosis Treatment
An experimental drug called TY1 reduced inflammation and scarring in lab studies of systemic sclerosis (SSc), according to a new study in JCI Insight, and researchers are now preparing to seek FDA approval to begin testing it in people.
Routine blood test may help flag lung disease risk in diffuse SSc, study says
A common, inexpensive blood test that measures inflammation (ESR) may help flag people with diffuse systemic sclerosis (SSc) who are more likely to have interstitial lung disease (ILD), according to a study in Turkey of 117 patients published in Therapeutic Advances in Respiratory Disease.
Study links cancer in scleroderma to timing and autoantibodies
Different types of cancer in people with systemic sclerosis (SSc) tend to appear at different points in the disease and are linked to different antibodies and complications, according to a large international study in Arthritis & Rheumatology that suggests cancer screening could be tailored accordingly.